1/28
A complete set of 24 vocabulary flashcards covering the components, mechanisms, comparative pathways, and failure modes of the phosphoinositide signaling pathway.
Phosphoinositide pathway
A signaling pathway that enables the hormone angiotensin II to stimulate vascular smooth muscle contraction, causing vasoconstriction and raising blood pressure.
Angiotensin II
The first messenger hormone that binds to a receptor on the extracellular surface of vascular smooth muscle cells.
Angiotensin II receptor
A G protein-coupled receptor on vascular smooth muscle cells that activates an intracellular G protein by swapping GDP for GTP upon ligand binding.
G protein (Phosphoinositide pathway)
A signaling protein that, when GTP-bound (switched on), activates the enzyme phospholipase C.
Phospholipase C (PLC)
An enzyme activated by a GTP-bound G protein that cleaves the plasma membrane lipid PIP2 into two second messengers: IP3 and DAG.
PIP2 (Phosphatidylinositol 4,5-bisphosphate)
A phospholipid located in the plasma membrane that serves as the starting substrate cleaved by phospholipase C.
IP3 (Inositol 1,4,5-trisphosphate)
A second messenger released into the cytoplasm that diffuses to the smooth endoplasmic reticulum and opens Ca2+ channels.
DAG (Diacylglycerol)
A second messenger that stays anchored in the plasma membrane and acts together with Ca2+ to activate protein kinase C.
Ca2+ (in Phosphoinositide pathway)
A second messenger released from the smooth endoplasmic reticulum that acts cooperatively with DAG to activate protein kinase C.
Protein kinase C (PKC)
The kinase activated by DAG and Ca2+ that drives the final cellular response of smooth muscle contraction (vasoconstriction).
Second messengers (Phosphoinositide pathway)
The three intracellular signaling molecules in the pathway: IP3, DAG, and Ca2+.
Facilitated diffusion of Ca2+
The passive transport mechanism whereby Ca2+ flows down its concentration gradient from high in the smooth ER to low in the cytoplasm via an IP3-gated channel without consuming ATP.
Vasoconstriction
The narrowing of blood vessels caused by vascular smooth muscle contraction, which raises blood pressure.
Angiotensin II receptor blockade
Pharmacological inhibition where a drug blocks the receptor, preventing G protein activation and halting downstream PLC, IP3, DAG, Ca2+, and PKC activity, which reduces vessel constriction and lowers blood pressure.
Loss of G protein GTPase activity
A malfunction where the G protein remains permanently GTP-bound (stuck on), causing continuous PLC and PKC activity, constant vasoconstriction, and high blood pressure.
G protein GTP-binding failure
A pathway failure where the G protein cannot bind GTP, resulting in Step 1 (angiotensin II binding) being the final working step, while PLC remains off and downstream signaling is halted.
Phospholipase C inhibition
A failure state where Step 2 (G protein activation) is the last functional step, preventing PIP2 cleavage and yielding no IP3, DAG, Ca2+ release, PKC activity, or vasoconstriction.
Blocked ER Ca2+ channels
A defect where IP3 fails to open smooth ER channels, making Step 3 (production of IP3 and DAG) the last functional step, leaving PKC not fully activated and preventing vasoconstriction.
Empty smooth ER Ca2+ stores
A scenario in which IP3 successfully opens channels but lacks Ca2+ to release, preventing full PKC activation and leaving vasoconstriction weak or absent.
PKC inhibitor
An agent that blocks vascular smooth muscle contraction without affecting upstream steps, allowing IP3 and Ca2+ levels to rise normally while vessel constriction fails to occur.
Membrane PIP2 depletion
A condition where phospholipase C is active but lacks substrate to cut, thereby preventing the formation of IP3 and DAG, Ca2+ release, PKC activation, and vasoconstriction.
Pathway blockade effect on blood pressure
The drop in blood pressure caused by inhibiting the pathway, which prevents angiotensin II from contracting vascular smooth muscle, leaving vessels wider with less resistance to flow.
step 1 of 7. Context: the hormone angiotensin II reaches vascular smooth muscle to raise blood pressure. What is the first step?
Angiotensin II binds its receptor (a G protein-coupled receptor) on the vascular smooth muscle cell.
step 2 of 7. Step 1: Angiotensin II binds its receptor. What happens next?
The receptor activates a G protein (GDP swapped for GTP), and the G protein activates phospholipase C (PLC)
step 3 of 7. Step 2: The G protein activates phospholipase C. What happens next?
Phospholipase C cuts PIP2 (a membrane lipid) into IP3 and DAG. IP3 is released into the cytoplasm, and DAG stays in the membrane.
step 4 of 7. Step 3: PLC cuts PIP2 into IP3 and DAG. What does IP3 do next?
P3 diffuses to the smooth ER and binds and opens Ca2+ channels in the ER membrane.
step 5 of 7. Step 4: IP3 opens Ca2+ channels on the smooth ER. What happens next?
Ca2+ flows out of the ER lumen (high Ca2+) into the cytoplasm, down its gradient
step 6 of 7. Step 5: Ca2+ floods into the cytoplasm. What happens next
Ca2+ and DAG (in the membrane) together activate protein kinase C (PKC)
step 7 of 7. Step 6: Ca2+ and DAG activate protein kinase C. What happens next?
PKC causes vasoconstriction (the smooth muscle contracts), which raises blood pressure.